We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

127 hedge funds and large institutions have $1.15B invested in Protagonist Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

31% more capital invested

Capital invested by funds: $875M → $1.15B (+$270M)

8% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 40

1% less funds holding

Funds holding: 128 → 127 (-1)

4% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 26

12.21% less ownership

Funds ownership: 113.41% → 101.2% (-12%)

28% less call options, than puts

Call options by funds: $810K | Put options by funds: $1.12M

Holders
127
Holders Change
-1
Holders Change %
-0.78%
% of All Funds
2.23%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.09%
New
25
Increased
43
Reduced
40
Closed
26
Calls
$810K
Puts
$1.12M
Net Calls
-$313K
Net Calls Change
+$374K

Top Buyers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
+$16.6M
2
RCAMU
Rothschild & Co Asset Management US
Connecticut
+$11M
3
BlackRock
BlackRock
New York
+$10.4M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.93M
5
OWP
Obermeyer Wealth Partners
Colorado
+$9.77M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$13.9M
2
BI
BVF Inc
California
-$7.95M
3
PA
Perceptive Advisors
New York
-$4.1M
4
RI
RTW Investments
New York
-$3.61M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
26
Opaleye Management
Massachusetts
$7.69M +$936K +37,000 +14%
Charles Schwab
27
Charles Schwab
California
$6.78M +$920K +36,367 +16%
TLP
28
Tri Locum Partners
New York
$6.66M -$55.6K -2,197 -0.8%
ACM
29
Altium Capital Management
New York
$6.17M +$1.33M +52,500 +28%
PAM
30
Panagora Asset Management
Massachusetts
$5.94M -$181K -7,169 -3%
SFM
31
Sphera Funds Management
Israel
$5.24M +$5.12M +202,134 New
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$5.21M -$3.44M -135,876 -40%
Citadel Advisors
33
Citadel Advisors
Florida
$5.13M -$3.61M -142,604 -42%
IBT
34
International Biotechnology Trust
United Kingdom
$3.94M – – –
LCM
35
Laurion Capital Management
New York
$3.82M +$436K +17,247 +13%
TLCM
36
Twin Lakes Capital Management
California
$3.7M +$10.1K +401 +0.3%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$3.46M +$109K +4,291 +3%
Citigroup
38
Citigroup
New York
$2.48M +$2.18M +86,013 +886%
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$2.4M -$1.1M -43,501 -33%
SEI Investments
40
SEI Investments
Pennsylvania
$2.25M +$2.2M +86,880 New
Marshall Wace
41
Marshall Wace
United Kingdom
$2.25M -$762K -30,103 -26%
Swiss National Bank
42
Swiss National Bank
Switzerland
$2.17M +$22.8K +900 +1%
Two Sigma Investments
43
Two Sigma Investments
New York
$2.16M -$1.84M -72,850 -47%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$1.97M +$1.57M +62,102 +448%
KCM
45
Kennedy Capital Management
Missouri
$1.96M +$1.91M +75,518 New
AG
46
Artal Group
Luxembourg
$1.94M -$1.47M -58,000 -44%
Allianz Asset Management
47
Allianz Asset Management
Germany
$1.92M – – –
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$1.75M -$202K -7,973 -11%
TD Asset Management
49
TD Asset Management
Ontario, Canada
$1.59M +$259K +10,219 +20%
Canada Pension Plan Investment Board
50
Canada Pension Plan Investment Board
Ontario, Canada
$1.43M +$1.39M +55,000 New
1
2
3 4 5

PTGX Hedge Fund Activity: Q1 2021 in Review

127 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2021, worth a combined $1.15B — up 31% from $875M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of PTGX and 25 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 43 added.

The largest buyer was Sofinnova Investments, opening a new position worth an estimated $16.6M. The largest seller was Adage Capital Partners, cutting an estimated $13.9M.

  • 127 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2021, down from 128 in Q4 2020.
  • Funds reported $1.15B of Protagonist Therapeutics stock for Q1 2021, up 31% quarter-over-quarter.
  • 25 funds opened new Protagonist Therapeutics positions in Q1 2021 and 26 closed out, a net change of -1 holder.
  • The largest Protagonist Therapeutics buyer in Q1 2021 was Sofinnova Investments, an estimated $16.6M added.
  • The largest Protagonist Therapeutics seller in Q1 2021 was Adage Capital Partners, an estimated $13.9M sold.

Based on aggregated 13F filings for Q1 2021.